Literature DB >> 1375156

Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia.

S Bremer1, T Hoof, M Wilke, R Busche, B Scholte, J R Riordan, G Maass, B Tümmler.   

Abstract

P-glycoprotein (MDR1), that confers multidrug resistance in cancer, and the cystic-fibrosis transmembrane-conductance regulator (CFTR), that is causative defective in cystic fibrosis, belong to the family of ATP-binding transport proteins. The expression of MDR1 and CFTR in human epithelial tissues and the cell lines T84 and HT29 was estimated by primer-directed reverse transcription (RT) and subsequent monitoring of the kinetics of cDNA product formation during the polymerase chain reaction (PCR). MDR1 mRNA was found in high levels, 15-50 amol mRNA/microgram RNA, in the intestine, kidney, liver and placenta, and in low levels, 0.2 amol/microgram RNA, in respiratory epithelium. Large amounts of CFTR mRNA were measured in the gastrointestinal tract, whereas the kidney, as the phenotypically normal organ, and the lung, as the most severely affected organ in cystic fibrosis, both contained low amounts, 3 amol CFTR/microgram RNA. CFTR transcript levels of 1-5 amol/microgram RNA were determined in lymphocytes and lymphoblast cell lines, suggesting that lymphoblasts are an accessible source for the study of the molecular pathogenesis of cystic fibrosis. When transcripts were scanned by overlapping RT/PCR analyses, only transcript of expected size was detected for MDR1 mRNA, where variable in-frame deletions of either exon 4, 9 or 12 were observed in CFTR mRNA. The complete loss of single exons was seen at proportions of 1-40% in all investigated tissues and cell lines with large donor-to-donor variation. Exons 9 and 12 of the CFTR gene encode parts of the evolutionarily well-conserved first nucleotide-binding fold including the two Walker motifs. Alternative splicing may give rise to various CFTR forms of different function and localization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375156     DOI: 10.1111/j.1432-1033.1992.tb16911.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  24 in total

1.  Expression of ATP-binding cassette multidrug transporters in the giant liver fluke Fasciola gigantica and their possible involvement in the transport of bile salts and anthelmintics.

Authors:  Supeecha Kumkate; Supatra Chunchob; Tavan Janvilisri
Journal:  Mol Cell Biochem       Date:  2008-06-10       Impact factor: 3.396

2.  CFTR transcripts are undetectable in lymphocytes and respiratory epithelial cells of a CF patient homozygous for the nonsense mutation R553X.

Authors:  K Will; J Reiss; M Dean; M Schlösser; R Slomski; J Schmidtke; M Stuhrmann
Journal:  J Med Genet       Date:  1993-10       Impact factor: 6.318

3.  Diversity of the abundant pKLC102/PAGI-2 family of genomic islands in Pseudomonas aeruginosa.

Authors:  Jens Klockgether; Dieco Würdemann; Oleg Reva; Lutz Wiehlmann; Burkhard Tümmler
Journal:  J Bacteriol       Date:  2006-12-28       Impact factor: 3.490

Review 4.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 5.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

6.  CFTR and differentiation markers expression in non-CF and delta F 508 homozygous CF nasal epithelium.

Authors:  F Dupuit; N Kälin; S Brézillon; J Hinnrasky; B Tümmler; E Puchelle
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.

Authors:  P J French; J H van Doorninck; R H Peters; E Verbeek; N A Ameen; C R Marino; H R de Jonge; J Bijman; B J Scholte
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

8.  Gene Therapy for Respiratory Diseases: Progress and a Changing Context.

Authors:  Eric W F W Alton; A Christopher Boyd; Jane C Davies; Deborah R Gill; Uta Griesenbach; Tracy E Harman; Stephen Hyde; Gerry McLachlan
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 5.695

9.  A termination mutation (2143delT) in the CFTR gene of German cystic fibrosis patients.

Authors:  T Dörk; N Kälin; M Stuhrmann; J Schmidtke; B Tümmler
Journal:  Hum Genet       Date:  1992-11       Impact factor: 4.132

10.  Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis mutations.

Authors:  T Dörk; R Fislage; T Neumann; B Wulf; B Tümmler
Journal:  Hum Genet       Date:  1994-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.